Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Slides:

Advertisements

Similar presentations

Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease.

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1)

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared.

CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological.

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients G. Venton,

Donor CD3+ lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: Single-center experience Jean El-Cheikh, Roberto.

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.

Biology of Blood and Marrow Transplantation

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia

Analysis of the Prognostic Effect of Peripheral Blood Lymphocyte and Monocyte Count after Autologous Hematopoietic Stem Cell Transplant in Refractory/Relapsed.

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation

Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide – a Single Institution Experience Reshma Ramlal, MD, Koji.

Killer Cell Immunoglobulin-Like Receptor–Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.

Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation.

Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma Jennifer A. Kanakry,

GVHD Prophylaxis with Post-Transplant High Dose Cyclophosphamide: Impact on Engraftment, Treatment-Related Mortality and Resource Utilization Nasheed.

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Comparison of Haploidentical T-Replete HSCT Followed with Post-Transplant High Dose Cyclophosphamide (PT-HDCy) with Matched Related (MRD) or Unrelated.

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Haploidentical T Cell–Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with.

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Similar Survival Between Haploidentical T-Cell Replete Hematopoietic Transplantation (Haplo) with Post-Transplantation Cyclophosphamide (PT-CY) and Unrelated.

Biology of Blood and Marrow Transplantation

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Presentation transcript:

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older Patients Raynier Devillier, Angela Granata, Sabine Fürst, MD, Samia Harbi, Catherine Faucher, Pierre Jean Weiller, Christian Chabannon, MD, PhD, Luca Castagna, Didier Blaise, MD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S369-S370 (March 2016) DOI: 10.1016/j.bbmt.2015.11.878 Copyright © 2016 Terms and Conditions

Figure 1: Outcome after Haplo-SCT; Cumulative incidence of acute GVHD (A); Cumulative incidence of chronic GVHD (B); Cumulative incidences of non-relapse mortality and relapse (C); Kaplan Meier estimate of progression free and overall survival (D). Biology of Blood and Marrow Transplantation 2016 22, S369-S370DOI: (10.1016/j.bbmt.2015.11.878) Copyright © 2016 Terms and Conditions